Diuretics in Heart Failure — MCQs
Drug used for euvolemic hyponatremia in patient with advanced congestive heart failure is?
Thiazide diuretics can be used for the treatment of all of these conditions EXCEPT :
A 65-year-old man with congestive heart failure presents with worsening bilateral pitting edema. What is the most appropriate next step in management?
The site of action of the loop diuretic furosemide is:
Which one of the following drugs causes increased concentration of Na+ & Cl- in urine with normal bicarbonate?
Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?
Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?
A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
In the presence of renal failure, which of the following should not be given?
The choice of antihypertensive medication also depends upon the co-morbid illness of the patient, and all of the following recommendations have been made except:
Diuretics in Heart Failure Indian Medical PG Practice Questions and MCQs
Question 1: Drug used for euvolemic hyponatremia in patient with advanced congestive heart failure is?
- A. Nesiritide
- B. Tolvaptan (Correct Answer)
- C. Metoprolol
- D. Hydrocortisone
Explanation: ***Tolvaptan*** - **Tolvaptan** is a selective **vasopressin V2-receptor antagonist** that promotes free water excretion (aquaresis) without significantly altering electrolyte balance, making it suitable for euvolemic hyponatremia [1]. - It works by blocking the action of **antidiuretic hormone (ADH)**, which is often elevated in patients with **congestive heart failure (CHF)** leading to water retention and hyponatremia [2]. *Nesiritide* - **Nesiritide** is a **recombinant human B-type natriuretic peptide (BNP)** that causes vasodilation and diuresis, but it is primarily used for acutely decompensated heart failure with signs of congestion, not specifically for euvolemic hyponatremia [1]. - While it can induce diuresis, its main role is to reduce **preload** and **afterload**, and it does not directly target the mechanism of euvolemic hyponatremia as effectively as an aquaretic agent [1]. *Metoprolol* - **Metoprolol** is a **beta-blocker** used to reduce heart rate and blood pressure, improving cardiac function in CHF patients. - It does not directly address **hyponatremia** and its mechanism of action is unrelated to water balance or sodium concentration. *Hydrocortisone* - **Hydrocortisone** is a **corticosteroid** used for conditions like adrenal insufficiency, inflammation, or allergic reactions. - It has no direct role in the management of **hyponatremia** or **congestive heart failure**.
Question 2: Thiazide diuretics can be used for the treatment of all of these conditions EXCEPT :
- A. Hypertension
- B. Hyperlipidemia (Correct Answer)
- C. Congestive Heart Failure
- D. Idiopathic hypercalciuria with nephrocalcinosis
Explanation: ***Hyperlipidemia***- Thiazide diuretics are **not used to treat hyperlipidemia** and can sometimes have a mild **adverse effect of causing dyslipidemia** (increased LDL cholesterol and triglycerides).- Their mechanism of action primarily involves diuresis and vasodilation, not directly affecting lipid metabolism.*Hypertension*- Thiazide diuretics are **first-line agents** for the treatment of hypertension, especially for uncomplicated cases [3].- They reduce blood pressure by increasing sodium and water excretion, leading to a decrease in **extracellular fluid volume** and peripheral vascular resistance [2].*Congestive Heart Failure*- Thiazide diuretics are effective in managing **fluid overload** and **edema** associated with congestive heart failure [2].- While loop diuretics are often preferred for severe heart failure due to their greater diuretic potency, thiazides can be beneficial in milder cases or as adjuncts.*Idiopathic hypercalciuria with nephrocalcinosis*- Thiazide diuretics are used to treat **idiopathic hypercalciuria** because they promote **calcium reabsorption** in the renal tubules, thereby reducing urinary calcium excretion [1].- This property helps prevent the formation of calcium-containing kidney stones and can be beneficial in patients with **nephrocalcinosis**.
Question 3: A 65-year-old man with congestive heart failure presents with worsening bilateral pitting edema. What is the most appropriate next step in management?
- A. Increase diuretic dose (Correct Answer)
- B. Add beta-blocker
- C. Start corticosteroids
- D. Prescribe ACE inhibitor
Explanation: ***Increase diuretic dose*** - Worsening **pitting edema** in a patient with **congestive heart failure** indicates fluid overload, and increasing the diuretic dose is the most direct and effective treatment [1]. - This aims to **reduce fluid retention** and alleviate symptoms like edema and congestion, improving the patient's hemodynamic status [1]. *Add beta-blocker* - Beta-blockers are crucial for **long-term management** of heart failure by improving cardiac function and survival, but they are typically initiated slowly in stable patients. - Adding a beta-blocker acutely in a patient with worsening fluid overload can exacerbate symptoms and is generally **contraindicated** if the patient is not euvolemic. *Start corticosteroids* - **Corticosteroids** have powerful **anti-inflammatory** and immunosuppressive effects but are not indicated for the management of fluid overload in heart failure [1]. - They can actually cause **sodium and fluid retention**, which would worsen the patient's edema and heart failure symptoms [1]. *Prescribe ACE inhibitor* - **ACE inhibitors** are foundational in heart failure therapy for reducing afterload and remodeling, but they do not directly address acute fluid overload [2]. - While beneficial for long-term management, initiating or increasing an ACE inhibitor would not be the most appropriate immediate step for acute worsening edema [2].
Question 4: The site of action of the loop diuretic furosemide is:
- A. Distal convoluted tubule
- B. Descending limb of loop of Henle
- C. Proximal convoluted tubule
- D. Thick ascending limb of loop of Henle (Correct Answer)
Explanation: ***Thick ascending limb of loop of Henle*** - Furosemide, a **loop diuretic**, acts by inhibiting the **Na+-K+-2Cl- cotransporter (NKCC2)** in the luminal membrane of the epithelial cells in the thick ascending limb. - This inhibition prevents the reabsorption of these ions, leading to increased excretion of **sodium**, **potassium**, **chloride**, and water. *Distal convoluted tubule* - This is the primary site of action for **thiazide diuretics**, which inhibit the **Na+-Cl- cotransporter**. - While some water reabsorption occurs here, it is not the main target for loop diuretics like furosemide. *Descending limb of loop of Henle* - This segment is primarily permeable to **water** due to aquaporins but impermeable to solutes, allowing for passive water reabsorption. - No significant transport mechanisms are directly targeted by furosemide here. *Proximal convoluted tubule* - The proximal tubule is where the majority of filtered **sodium**, **water**, and other solutes are reabsorbed. - **Carbonic anhydrase inhibitors** (e.g., acetazolamide) primarily act here.
Question 5: Which one of the following drugs causes increased concentration of Na+ & Cl- in urine with normal bicarbonate?
- A. Furosemide
- B. Ethacrynic acid (Correct Answer)
- C. Bumetanide
- D. Acetazolamide
Explanation: ***Ethacrynic acid*** - Ethacrynic acid is a **loop diuretic** that inhibits the Na+-K+-2Cl- cotransporter in the **thick ascending limb of the loop of Henle**. - It causes increased urinary excretion of **Na+ and Cl-** while maintaining **normal bicarbonate levels** (does not affect carbonic anhydrase). - **Key distinguishing feature**: Ethacrynic acid is a **phenoxyacetic acid derivative** (NOT a sulfonamide), making it useful in patients with **sulfonamide allergies**. - Note: All loop diuretics share the property of increasing Na+ and Cl- excretion with normal bicarbonate. *Furosemide* - Furosemide is a **sulfonamide-derived loop diuretic** with the same mechanism as ethacrynic acid (inhibits Na+-K+-2Cl- cotransporter). - It also increases Na+ and Cl- excretion with normal bicarbonate levels. - While pharmacologically equivalent to ethacrynic acid for this effect, it is structurally different (sulfonamide derivative). *Bumetanide* - Bumetanide is another **sulfonamide-derived loop diuretic** with identical mechanism to furosemide and ethacrynic acid. - It produces the same electrolyte effects: increased Na+ and Cl- excretion with normal bicarbonate. - Structurally, it is a sulfonamide derivative like furosemide. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** acting in the **proximal tubule**. - It increases excretion of **bicarbonate** (causing metabolic acidosis), along with Na+ and K+. - This would result in **elevated bicarbonate in urine**, NOT normal bicarbonate, making it incorrect.
Question 6: Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?
- A. Carvedilol
- B. Spironolactone (Correct Answer)
- C. Abiraterone
- D. Sacubitril/Valsartan
Explanation: ***Spironolactone*** - **Spironolactone** is a **potassium-sparing diuretic** that acts as a **competitive antagonist of aldosterone** receptors, primarily in the collecting ducts of the kidneys. - This action leads to increased excretion of sodium and water, and retention of potassium, which is beneficial in **heart failure** by reducing fluid overload and mitigating the detrimental effects of aldosterone on cardiac remodeling. *Carvedilol* - **Carvedilol** is a **beta-blocker** with additional **alpha-1 blocking** properties, commonly used in heart failure to reduce heart rate, blood pressure, and myocardial oxygen demand. - It does not possess significant aldosterone antagonistic properties. *Sacubitril/Valsartan* - **Sacubitril/Valsartan** is an **angiotensin receptor-neprilysin inhibitor (ARNI)**. Valsartan is an **angiotensin receptor blocker (ARB)**, and sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. - While it modulates the **renin-angiotensin-aldosterone system (RAAS)** and is highly effective in heart failure, it does not directly antagonize aldosterone receptors. *Abiraterone* - **Abiraterone** is an **androgen-biosynthesis inhibitor** used in the treatment of **prostate cancer**. - Its primary mechanism involves inhibiting **CYP17**, an enzyme critical for androgen production, and it has no role in the management of heart failure or aldosterone antagonism.
Question 7: Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?
- A. Spironolactone (Correct Answer)
- B. Amiloride
- C. Triamterene
- D. Eplerenone
Explanation: ***Spironolactone*** - **Spironolactone** was the first potassium-sparing diuretic shown to reduce **cardiac mortality** in patients with **chronic heart failure** in the **RALES trial** (Randomized Aldactone Evaluation Study). - Its beneficial effects in heart failure are primarily attributed to its **aldosterone receptor antagonist** properties, which counteract the harmful effects of aldosterone on the myocardium and vasculature, rather than just its diuretic effect. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that works by directly inhibiting **epithelial sodium channels (ENaC)** in the collecting duct. - While it helps in potassium conservation, it has not been shown to significantly reduce cardiac mortality in chronic heart failure patients in clinical trials. *Triamterene* - **Triamterene** is another potassium-sparing diuretic that also directly inhibits **ENaC** in the collecting duct, similar to amiloride. - Like amiloride, it is used to prevent hypokalemia but lacks evidence for significant **cardiac mortality reduction** in chronic heart failure. *Eplerenone* - **Eplerenone** is a selective **aldosterone receptor antagonist**, similar to spironolactone, with fewer hormonal side effects. - While it has been shown to reduce **cardiac mortality** in chronic heart failure (e.g., in the EMPHASIS-HF trial), it was introduced later than spironolactone and was not the *first* to demonstrate this benefit.
Question 8: A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
- A. Hepatotoxicity
- B. Pulmonary fibrosis
- C. Fluid retention (Correct Answer)
- D. Hypokalemia
Explanation: ***Fluid retention***- **Pioglitazone**, a thiazolidinedione (TZD), commonly causes **fluid retention** or edema [1].- This fluid retention can **exacerbate heart failure** symptoms and lead to cardiac decompensation, especially in patients with pre-existing heart conditions [1].*Hepatotoxicity*- While TZDs like pioglitazone have been associated with **liver dysfunction** in some cases, significant hepatotoxicity is rare and usually not the primary concern or most common serious side effect [1].- **Regular monitoring of liver enzymes** is recommended, but fluid retention leading to heart failure exacerbation is a more immediate and severe risk in this patient profile.*Pulmonary fibrosis*- **Pulmonary fibrosis** is not a known or common complication directly associated with pioglitazone use.- This complication is typically linked to other medications or systemic diseases.*Hypokalemia*- **Hypokalemia**, or low potassium levels, is generally not a direct side effect of pioglitazone.- Electrolyte imbalances associated with heart failure or diuretic use, rather than pioglitazone itself, are more likely causes of hypokalemia.
Question 9: In the presence of renal failure, which of the following should not be given?
- A. Bumetanide
- B. Furosemide
- C. Spironolactone (Correct Answer)
- D. None of the options
Explanation: ***Spironolactone*** - **Spironolactone** is an **aldosterone antagonist**, a **potassium-sparing diuretic**, which can cause **hyperkalemia**, especially in patients with **renal impairment** where potassium excretion is already compromised - Due to the risk of severe **hyperkalemia**, which can lead to life-threatening **cardiac arrhythmias**, spironolactone is **contraindicated** or used with extreme caution in **renal failure** - In renal failure, the kidneys cannot adequately excrete potassium, and adding a potassium-sparing diuretic significantly increases the risk of dangerous hyperkalemia *Bumetanide* - **Bumetanide** is a **loop diuretic** that primarily acts on the **ascending limb of the loop of Henle** to inhibit sodium and chloride reabsorption - While its efficacy may be reduced in severe renal failure, it is still commonly used at higher doses and can be effective in managing fluid overload in these patients - Loop diuretics remain the mainstay of diuretic therapy in renal failure, unlike potassium-sparing diuretics *Furosemide* - **Furosemide** is another **loop diuretic** that is often used in patients with **renal failure** to promote diuresis and manage fluid overload - Even with impaired kidney function, it can still exert its diuretic effect, although higher doses may be required - It does not cause significant potassium retention and is safe to use in renal failure *None of the options* - This option is incorrect because **spironolactone** is specifically contraindicated in patients with **renal failure** due to the high risk of **hyperkalemia**
Question 10: The choice of antihypertensive medication also depends upon the co-morbid illness of the patient, and all of the following recommendations have been made except:
- A. In hypertensive patients with gout, diuretics are the first-line treatment. (Correct Answer)
- B. In hypertensive patients with heart failure, ACE inhibitors may be preferred
- C. In hypertensive patients with migraine, beta blockers are an excellent choice
- D. In hypertensive patients with peripheral vascular disease, calcium channel blockers are recommended
Explanation: ***In hypertensive patients with gout, diuretics are the first-line treatment.*** * This statement is incorrect because **diuretics**, particularly **thiazide diuretics**, can **elevate uric acid levels** and precipitate or worsen gout attacks. * Therefore, they are generally **contraindicated or used with caution** in patients with gout, not recommended as first-line treatment. *In hypertensive patients with heart failure, ACE inhibitors may be preferred* * **ACE inhibitors** are a cornerstone of heart failure treatment due to their ability to **improve cardiac remodeling**, reduce mortality, and alleviate symptoms. * They are often preferred for their **vasodilatory effects** and ability to prevent volume overload, which benefits patients with heart failure. *In hypertensive patients with migraine, beta blockers are an excellent choice* * **Beta-blockers**, such as propranolol, are effective in both **blood pressure control** and the **prophylaxis of migraines** [1]. * This makes them an excellent choice for a hypertensive patient who also suffers from migraines, offering a dual therapeutic benefit [1]. *In hypertensive patients with peripheral vascular disease, calcium channel blockers are recommended* * **Calcium channel blockers (CCBs)**, especially dihydropyridines like amlodipine, are beneficial in peripheral vascular disease (PVD) due to their **vasodilatory effects**. * They can **improve blood flow** to the extremities, which is crucial in PVD, without negatively impacting symptoms like claudication.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free